Recent Updates
Recently added Catalysts

JNS002

Phase 1

Multiple Myeloma | Small molecule | Oncology |Johnson & Johnson|Last Updated: Jul 4, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment3

FDA Designations

No designations recorded

Clinical trial landscape

JNS002 · 1 trial · 1 indication

Phase 1 1
NCT01371227A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple MyelomaMultiple Myeloma
COMPLETED3 Analytics
PHASE1COMPLETED
A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
NCT013712273
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of patients with adverse events as a measure of safety and tolerability
Up to 21 days

Secondary Endpoints

Number of subjects who achieved a complete response or partial response
Up to 126 days
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
JNS002EXPERIMENTALJNS002 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.

Interventions

NameTypeDescription
JNS002DRUG30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Patients confirmed diagnosis of multiple myeloma with evaluable disease parameters (1.Presence of M-protein in the serum and/or urine, 2.Increased plasma cells in the bone marrow or biopsy-proven plasmacytoma, 3.Presence of related organ tissue impairment) * Patients with prog...

Countries:Japan
Unlock Eligibility Criteria

Competitive Landscape -Multiple Myeloma 221 trials

Top 20 of 25 competitors

CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV16PHASE3Pomalidomide, Dexamethasone, Venetoclax
Bristol-Myers Squibb CompanyBMY18PHASE3Iberdomide, Lenalidomide
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK5PHASE3IGI, 10%
GSK plc Sponsored ADRGSK17PHASE3Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Johnson & JohnsonJNJ28PHASE3Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone
Regeneron Pharmaceuticals, Inc.REGN11PHASE3Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide
Pfizer Inc.PFE11PHASE3Elranatamab, Lenalidomide
Sanofi SA Sponsored ADRSNY17PHASE3Isatuximab, Dexamethasone, Pomalidomide, Montelukast, Paracetamol/ Acetaminophen
AstraZeneca PLCAZN5PHASE3AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib
Gilead Sciences, Inc.GILD3PHASE3Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib
Karyopharm Therapeutics, Inc.KPTI6PHASE3Selinexor, Elotuzumab, Pomalidomide, Dexamethasone
Grifols, S.A. Sponsored ADR Class BGRFS1PHASE3Xembify
BioLineRX Ltd. Sponsored ADRBLRX1PHASE3BL-8040/kg, G-CSF
C4 Therapeutics, Inc.CCCC3PHASE2Cemsidomide, Dexamethasone
Cellectar Biosciences, Inc.CLRB1PHASE2Iopofosine I 131 single dose, Iopofosine I 131 fractionated dose
GeoVax Labs, Inc.GOVX1PHASE2COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Autolus Therapeutics Plc Sponsored ADRAUTL1PHASE2AUTO CAR T cell therapy
Incyte CorporationINCY2PHASE1Ruxolitinib, Lenalidomide, Methylprednisolone
Moderna, Inc.MRNA2PHASE1mRNA-2808
BeOne Medicines Ltd. Sponsored ADRONC1PHASE1Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide
Unlock Competitive Intelligence

Frequently asked questions about JNS002

What is JNS002 used for?

JNS002 is an investigational small molecule being studied for the treatment of multiple myeloma. It is a liposomal formulation of doxorubicin hydrochloride, designed for use in patients with relapsed or refractory disease. The drug is currently in early clinical development and has not been approved by regulatory authorities.

Who makes JNS002?

JNS002 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical research on this investigational oncology drug for multiple myeloma.

What phase is JNS002 in?

JNS002 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being evaluated in clinical trials for safety and efficacy in patients with multiple myeloma.

What clinical trials is JNS002 in?

JNS002 has been studied in one completed Phase 1 clinical trial, identified by the National Clinical Trial number NCT01371227. This trial evaluated the drug in patients with relapsed or refractory multiple myeloma in Japan, enrolling a total of 3 participants.

Is JNS002 the same as doxorubicin hydrochloride liposome injection?

Yes, JNS002 is also known as doxorubicin hydrochloride liposome injection. The clinical trial for JNS002, NCT01371227, specifically evaluated this liposomal formulation of doxorubicin in patients with relapsed or refractory multiple myeloma.